AR072559A1 - Amidas sustituidas, composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades mediadas por dgat1. - Google Patents

Amidas sustituidas, composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades mediadas por dgat1.

Info

Publication number
AR072559A1
AR072559A1 ARP090102662A ARP090102662A AR072559A1 AR 072559 A1 AR072559 A1 AR 072559A1 AR P090102662 A ARP090102662 A AR P090102662A AR P090102662 A ARP090102662 A AR P090102662A AR 072559 A1 AR072559 A1 AR 072559A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
hetero
alkylene
alkenylene
cycloalkyl
Prior art date
Application number
ARP090102662A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41136646&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR072559A1 publication Critical patent/AR072559A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Estos compuestos son utiles para el tratamiento de los trastornos mediados por acil-transferasa de acil-CoA-diacilglicerol 1 (DGAT1), por ejemplo, trastornos metabolicos. Su uso en el tratamiento de estos trastornos, y las composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de la formula (1) o un derivado farmacéuticamente aceptable del mismo, en donde R3 es H o alquilo C1-10 opcionalmente sustituido, heteroalquilo C1-10, -(Alkb)g-cicloalquilo C3-10, -(Alkb)g-heterocicloalquilo C3-10, alquenilo C2-10, hetero-alquenilo C2-10, -(Alkb)g-cicloalquenilo C3-10, -(Alkb)g-heterocicloalquenilo C3-10, alquinilo C2-10, heteroalquinilo C2-10, -(Alkb)g-ariIo C6-14, -(Alkb)g-heteroarilo (en donde heteroarilo contiene de 6 a 13 miembros del anillo), en donde. Alkb es alquileno C1-6 o hetero-alquileno C1-6 opcionalmente sustituidos, g es 0 o 1; r es 0 o 1; Z es O o NR6, en donde R6 es H o alquilo C1-6 opcionalmente sustituido, heteroalquilo C1-6, cicloalquilo C3-6, hetero-cicloalquilo C3-6, alquenilo C2-6, heteroalquenilo C2-6, cicloalquenilo C3-6, hetero-cicloalquenilo C3-6, fenilo, o heteroarilo que contiene 5 o 6 miembros del anillo; s es 0 o 1; M es -C(O)- o -S(O)t-, en donde: t es 1 o 2; R4 es H o alquilo C1-6 opcionalmente sustituido, heteroalquilo C1-6, cicloalquilo C3-6, hetero-cicloalquilo C3-6, alquenilo C2-6, heteroalquenilo C2-6, cicloalquenilo C3-6, hetero-cicloalquenilo C3-6, fenilo, o heteroarilo que contiene 5 o 6 miembros del anillo; R1 y R2 son independientemente H o alquilo C1-6 opcionalmente sustituido, heteroalquilo C1-6, -(Alkc)h-cicloalquilo C3-6, -(Alkc)h-hetero-cicloalquilo C3-6, alquenilo C2-6, hetero-alquenilo C2-6, -(Alkc)h-cicloalquenilo C3-6, -(Alkc)h-hetero-cicloalquenilo C3-6, -(Alkc)h-fenilo, o -(Alkc)h-heteroariIo (en donde heteroarilo contiene 5 o 6 miembros del anillo), en donde AIkc es independientemente alquileno C1-6 o hetero-alquileno C1-6 opcionalmente sustituidos, h es independientemente 0 o 1; R5 es H o alquilo C1-6 opcionalmente sustituido, heteroalquilo C1-6, cicloalquilo C3-6, hetero-cicloalquilo C3-6, alquenilo C2-6, heteroalquenilo C2-6, cicloalquenilo C3-6, hetero-cicloalquenilo C3-6, fenilo, o heteroarilo que contiene 5 o 6 miembros del anillo: o uno de R1 y R4 forman juntos alquileno C3-5, alquenileno C3-5, hetero-alquileno C3-5, o hetero-alquenileno C3-5 opcionalmente sustituidos; R1 y R2 forman juntos alquileno C2-8, alquenileno C2-8, hetero-alquileno C2-8, o hetero-alquenileno C2-8 opcionalmente sustituidos; o R1 y R5 forman juntos alquileno C2-4, alquenileno C2-4, hetero-alquileno C2-4, o hetero-alquenileno C2-4 opcionalmente sustituidos; A es heteroarilo opcionalmente sustituido que contiene de 5 a 13 miembros del anillo; a es de 0 a 3; b es de 0 a 3;R10a es -Q-R7a, y R10b es -R7b, en donde Q es independientemente alquileno C1-6, hetero-alquileno C1-6, alquenileno C2-6 o hetero-alquenileno C2-6 opcionalmente sustituidos, u O, S, NR8, o -C(O)-, en donde R8 es H o alquilo C1-6 opcionalmente sustituido; y R7a es H o alquilo C1-10 opcionalmente sustituido, heteroalquilo C1-10, cicloalquilo C3-10, hetero-cicloalquilo C3-10, arilo C6-14 o heteroarilo que contiene de 5 a 13 miembros del anillo, R7b es alquilo C1-10 opcionalmente sustituido, heteroalquilo C1-10, cicloalquilo C3-10, hetero-cicloalquilo C3-10, arilo C6-14 o heteroarilo que contiene de 5 a 13 miembros del anillo; y en el entendido de que cuando menos uno de R3 y R4 no es H.
ARP090102662A 2008-07-15 2009-07-14 Amidas sustituidas, composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades mediadas por dgat1. AR072559A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8091308P 2008-07-15 2008-07-15

Publications (1)

Publication Number Publication Date
AR072559A1 true AR072559A1 (es) 2010-09-08

Family

ID=41136646

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102662A AR072559A1 (es) 2008-07-15 2009-07-14 Amidas sustituidas, composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades mediadas por dgat1.

Country Status (23)

Country Link
US (1) US8703761B2 (es)
EP (4) EP2548618A3 (es)
JP (1) JP5401544B2 (es)
KR (1) KR20110028661A (es)
CN (1) CN102119047B (es)
AR (1) AR072559A1 (es)
AU (1) AU2009272826A1 (es)
BR (1) BRPI0916216A2 (es)
CA (1) CA2731097A1 (es)
CL (1) CL2011000087A1 (es)
CO (1) CO6341581A2 (es)
CR (1) CR20110013A (es)
EA (1) EA201100189A1 (es)
EC (1) ECSP11010830A (es)
IL (1) IL210292A0 (es)
MA (1) MA32558B1 (es)
MX (1) MX2011000628A (es)
NZ (1) NZ590285A (es)
PE (1) PE20110105A1 (es)
SV (1) SV2011003809A (es)
TW (1) TW201006832A (es)
UY (1) UY31986A (es)
WO (1) WO2010007046A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US7863309B2 (en) * 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
AU2010216632A1 (en) * 2009-02-17 2011-08-04 Msd K.K. 1,4-benzodiazepin-2-on derivatives
EP2903985A1 (en) * 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
TWI691486B (zh) 2016-01-29 2020-04-21 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
CN110913859A (zh) 2017-07-27 2020-03-24 东丽株式会社 圆形脱毛症的治疗剂或预防剂
MD3664802T2 (ro) 2017-08-07 2022-07-31 Alkermes Inc Inhibitori biciclici ai deacetilazei histonei
EP3746124A4 (en) * 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND USES THEREOF
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
KR20200139696A (ko) 2018-04-04 2020-12-14 니뽄 다바코 산교 가부시키가이샤 헤테로아릴로 치환된 피라졸 화합물 및 그의 의약 용도
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
BR112022014949A2 (pt) * 2020-01-29 2022-09-27 Foghorn Therapeutics Inc Compostos e usos dos mesmos
AU2021213257A1 (en) * 2020-01-29 2022-08-25 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4214200A1 (en) 2020-10-22 2023-07-26 Nimmune Biopharma, Inc. Lancl ligands
TWD226926S (zh) 2022-09-21 2023-08-11 精誠軟體服務股份有限公司 電腦程式之具變化外觀之圖形化使用者介面
TWD226927S (zh) 2022-09-21 2023-08-11 精誠軟體服務股份有限公司 電腦程式之具變化外觀之圖形化使用者介面
KR20240140019A (ko) * 2023-03-15 2024-09-24 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 약학적 조성물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526938A (en) * 1974-12-19 1978-10-04 Shell Int Research Derivatives of n-phenyl-n-aroylalanine and herbicidal compositions containing them
CA1160234A (en) * 1980-10-30 1984-01-10 Masahiko Nagakura Thiadiazole derivatives and process for preparing same
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
FR2763337B1 (fr) 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
AU6229699A (en) 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
WO2000044731A1 (en) 1999-01-27 2000-08-03 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
JP2003535046A (ja) 2000-04-03 2003-11-25 デュポン ファーマシューティカルズ カンパニー Ａβタンパク質産生の阻害剤としての環状ラクタム
CA2420727A1 (en) * 2000-10-26 2002-05-02 Sanofi-Synthelabo Triazole derivatives and pharmaceutical compositions comprising them
US6841566B2 (en) * 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP4164645B2 (ja) * 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
CA2501799C (en) * 2002-10-09 2008-06-17 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
CN1688557A (zh) * 2002-10-09 2005-10-26 辉瑞产品公司 用于治疗神经变性疾病的噻唑化合物
ATE467616T1 (de) * 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
DE602004023080D1 (de) 2003-05-20 2009-10-22 Novartis Ag N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
KR20070002081A (ko) * 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
MXPA06011868A (es) 2004-04-14 2007-03-21 Amgen Inc Aril sulfonas y usos relacionados con las mismas.
JP2006089485A (ja) 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP4819686B2 (ja) 2004-09-24 2011-11-24 ミドリ安全株式会社 靴底及び靴
DE102004047840A1 (de) * 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
FR2876692B1 (fr) * 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
TW200843761A (en) * 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
EP1845081A4 (en) 2005-02-01 2009-03-25 Takeda Pharmaceutical amide
CN101171231A (zh) * 2005-05-10 2008-04-30 霍夫曼-拉罗奇有限公司 二酰基甘油酰基转移酶抑制剂
JP2008542276A (ja) 2005-05-23 2008-11-27 メルク エンド カムパニー インコーポレーテッド プロリンビスアミドオレキシン受容体アンタゴニスト
TWI329641B (en) * 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
WO2007060140A2 (en) * 2005-11-28 2007-05-31 F. Hoffmann-La Roche Ag Inhibitors of diacyglycerol acyltransferase (dgat)
EP2007716A1 (en) 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
EP2044055A4 (en) * 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
TW200827340A (en) * 2006-11-10 2008-07-01 Astrazeneca Ab Chemical compounds
JP2008133218A (ja) 2006-11-28 2008-06-12 Hokko Chem Ind Co Ltd フェノキシ酪酸アミド誘導体および除草剤
CA2716515A1 (en) * 2008-02-21 2009-08-27 Boehringer Ingelheim International Gmbh Amine and ether compounds which modulate the cb2 receptor

Also Published As

Publication number Publication date
CL2011000087A1 (es) 2011-07-01
CO6341581A2 (es) 2011-11-21
JP2011528016A (ja) 2011-11-10
IL210292A0 (en) 2011-03-31
BRPI0916216A2 (pt) 2018-03-13
US20100022513A1 (en) 2010-01-28
SV2011003809A (es) 2011-07-05
EP2380631A1 (en) 2011-10-26
KR20110028661A (ko) 2011-03-21
TW201006832A (en) 2010-02-16
MX2011000628A (es) 2011-02-25
WO2010007046A3 (en) 2010-07-22
NZ590285A (en) 2012-10-26
CN102119047B (zh) 2014-09-24
EP2349484A2 (en) 2011-08-03
WO2010007046A2 (en) 2010-01-21
CN102119047A (zh) 2011-07-06
AU2009272826A1 (en) 2010-01-21
UY31986A (es) 2010-02-26
EP2559455A1 (en) 2013-02-20
US8703761B2 (en) 2014-04-22
EP2548618A2 (en) 2013-01-23
PE20110105A1 (es) 2011-02-25
EP2548618A3 (en) 2013-02-27
ECSP11010830A (es) 2011-03-31
CA2731097A1 (en) 2010-01-21
CR20110013A (es) 2011-02-11
EA201100189A1 (ru) 2011-08-30
MA32558B1 (fr) 2011-08-01
JP5401544B2 (ja) 2014-01-29

Similar Documents

Publication Publication Date Title
AR072559A1 (es) Amidas sustituidas, composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades mediadas por dgat1.
AR075789A1 (es) Derivados de bencimidazol, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de la prostaglandina microsomica e2 sintasa-1 (mpnges-1)
AR124662A2 (es) Formulaciones inmunosupresoras
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
PE20081776A1 (es) Moduladores 2-aminopirimidina del receptor histamina h4
IN2014MN00258A (es)
CY1108445T1 (el) Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν
NZ593951A (en) Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
NZ603643A (en) Purinone derivative
EA201171066A1 (ru) Новые замещенные производные бензоксазола, бензимидазола, оксазолопиридина и имидазопиридина в качестве модуляторов гамма-секретазы
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR056086A1 (es) DERIVADOS DE 4-FENIL-PIRIMIDINA-6-SUSTITUíDA-2-CARBONITRILO, COMPOSICION FARMACEUTICA QUE LOS COMPRENDE Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON CATEPSINA K Y CATEPSINA S
EA201290654A1 (ru) Новые замещенные триазольные производные как модуляторы гамма-секретазы
AR084412A1 (es) Compuestos de piridina fusionados, utiles como inhibidores de caseina quinasa, y las composiciones farmaceuticas que los contienen
RS54785B1 (sr) Pirolopirazin-spirociklični piperidin amidi kao modulatori jonskih kanala
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
PE20090042A1 (es) Analogos de ciclopamina
AR083167A1 (es) Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas
AR074966A1 (es) Compuestos amino-heterociclicos
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
EA201270166A1 (ru) Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
RU2009148320A (ru) Производные пиперидина/пиперазина

Legal Events

Date Code Title Description
FA Abandonment or withdrawal